Test Announcement: SARS-CoV-2 Antibodies, Spike Protein

February 5, 2021 - PathGroup is pleased to announce the availability of a new serologic test for the detection of human antibodies to the SARS-CoV-2 spike protein (S) receptor binding domain (RBD), the viral pathogen associated with SARS-CoV-2 (COVID-19). The Roche Elecsys® Anti-SARS-CoV-2 S antibody test is for the qualitative and semi-quantitative detection of total antibodies (IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection and is intended to aid in identification of patients with an adaptive immune response to SARS-CoV-2 indicating prior infection to the SARS-CoV-2 virus. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for this test.

 

Click Here to learn more.

Test Announcement: SARS-CoV-2 Antibodies, Spike Protein

February 5, 2021 - PathGroup is pleased to announce the availability of a new serologic test for the detection of human antibodies to the SARS-CoV-2 spike protein (S) receptor binding domain (RBD), the viral pathogen associated with SARS-CoV-2 (COVID-19). The Roche Elecsys® Anti-SARS-CoV-2 S antibody test is for the qualitative and semi-quantitative detection of total antibodies (IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection and is intended to aid in identification of patients with an adaptive immune response to SARS-CoV-2 indicating prior infection to the SARS-CoV-2 virus. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for this test.

 

Click Here to learn more.